Overall, our research indicated that GnT-V may be a useful therapeutic target to treat diabetic cardiomyopathy, primarily in the inhibition of myocardial hypertrophy and fibrosis. The gene discussed is MGAT5; the disease is diabetic cardiomyopathy.